ABCL — AbCellera Biologics Share News
0.000.00%
- $3.75bn
- $2.99bn
- $75.13m
AbCellera Initiated with Buy at Goldman
U.S. STOCKS ON THE MOVE-Reviva, AbCellera, Verizon
Brief: Abcellera And Abbvie Partner To Advance New Antibody Therapies
AbCellera up on partnership with AbbVie for antibody therapies
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
U.S. STOCKS ON THE MOVE-Gold miners, Kroger, Dollar General, Nutanix
AbCellera rises on rare disease alliance with Rallybio
Brief: Abcellera & Rallybio To Develop Novel Antibody-Based Therapeutics For Rare Diseases
Brief: Abcellera And Rallybio Announce Strategic Alliance To Discover, Develop And Commercialize Novel Antibody-Based Therapeutics For Rare Diseases
FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab (updated)
U.S. STOCKS ON THE MOVE-Wendy's, Corebridge, Riskified
U.S. STOCKS ON THE MOVE-Trade Desk, PolarityTE, Axon, Disney, Meta
U.S. STOCKS ON THE MOVE-Tesla, Canopy Growth, Merrimack Pharma
AbCellera rises on strong Q3 sales of COVID drug
Abcellera Biologics Inc reports results for the quarter ended in September - Earnings Summary
AbCellera falls as FDA says co's bebtelovimab may not neutralize new COVID subvariants
Abcellera Biologics Inc expected to post earnings of 5cents a share - Earnings Preview
Brief: Abcellera’s First Program With Regeneron Advances In Preclinical Development
Abcellera Biologics Inc reports results for the quarter ended in June - Earnings Summary